Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort

J Ose; RT Fortner; H Schock; PH Peeters; NC Onland-Moret; HB Bueno-de-Mesquita; E Weiderpass; IT Gram; K Overvad; A Tjonneland; L Dossus; A Fournier; L Baglietto; A Trichopoulou; V Benetou; D Trichopoulos; H Boeing; G Masala; V Krogh; A Matiello; R Tumino; M Popovic; M Obon-Santacana; N Larranaga; E Ardanaz; M-J Sanchez; V Menendez; M-D Chirlaque; RC Travis; K-T Khaw; J Braendstedt; A Idahl; E Lundin; S Rinaldi; E Kuhn; I Romieu; MJ Gunter; MA Merritt; E Riboli; R Kaaks

Journal article

Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort

J Ose, RT Fortner, H Schock, PH Peeters, NC Onland-Moret, HB Bueno-de-Mesquita, E Weiderpass, IT Gram, K Overvad, A Tjonneland, L Dossus, A Fournier, L Baglietto, A Trichopoulou, V Benetou, D Trichopoulos, H Boeing, G Masala, V Krogh, A Matiello Show all

British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2015

DOI: 10.1038/bjc.2014.566

Download PDF

Abstract

BACKGROUND: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics. METHODS: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n=565 cases). Multivariable conditional logistic regression models were used to estimate associations. RESULTS: We observed no association between IGF-I and EOC overall or by tumour characteristics. CONCLUSIONS: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diag..

View full abstract

University of Melbourne Researchers

Laura Baglietto Author Melbourne School of Population and Global Health

Grants

Awarded by Deutsche Krebshilfe

Awarded by Federal Ministry of Education and Research (Germany)

Awarded by Health Research Fund (FIS) of the Spanish Ministry of health

Awarded by Regional Government of Murcia

Awarded by Navarra, ISCIII RETIC (Spain)

Awarded by Cancer Research UK

Awarded by Medical Research Council

Awarded by National Institute for Health Research

Funding Acknowledgements

We thank all the EPIC participants for their invaluable contribution to the study. The German Cancer Research Center, Division of Cancer Epidemiology (Principal Investigator: Rudolf Kaaks) funded the analysis of IGF-I for this study. The European Prospective Investigation into Cancer and Nutrition is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); Deutsche Krebshilfe (70-2488), Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany; Grant 01-EA-9401); Hellenic Health Foundation (Greece) and the Stavros Niarchos Foundation; Italian Association for Research on Cancer (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway); Health Research Fund (FIS) of the Spanish Ministry of health (Exp 96/0032), Regional Governments of Andalucia, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK, Medical Research Council (United Kingdom).